ICON, a globally renowned healthcare intelligence and clinical research organization, has announced that its Chief Financial Officer, Brendan Brennan, will be stepping down from his position in the fourth quarter of this year to pursue an opportunity outside the CRO…
Updated findings on overall survival (OS) from a planned evaluation, encompassing around 75% of data, reveal an OS hazard ratio below 1.0 (HR<1.0) within the intent-to-treat (ITT) population, not adjusted for cross-over. Consistency is observed in radiographic progression-free survival (rPFS)…
Eisai Co., Ltd. (based in Tokyo, CEO: Haruo Naito) and Biogen Inc. (headquartered in Cambridge, Massachusetts, CEO: Christopher A. Viehbacher) have jointly announced the submission of a Supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA).…
Bristol Myers Squibb (NYSE: BMY) has announced the successful results of the pivotal Phase 3 KRYSTAL-12 study, which evaluated KRAZATI® (adagrasib) as a monotherapy for patients with previously treated locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring a…
Bristol Myers Squibb (NYSE: BMY) provided an update today following the preliminary analysis of findings from the first of two induction studies within the Phase 3 YELLOWSTONE clinical trial program, which assesses Zeposia (ozanimod) in adult patients dealing with moderate…
Novo Nordisk and Cardior Pharmaceuticals have announced a significant acquisition deal, with Novo Nordisk set to acquire Cardior for up to 1.025 billion Euros. This includes an upfront payment along with additional payments contingent upon the achievement of specific developmental…
Novo Nordisk has announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has provided a positive opinion, recommending the marketing authorization for Awiqli® (the branded name for once-weekly basal insulin icodec) for the treatment of…
Gilead Sciences, Inc. (Nasdaq: GILD) has finalized its acquisition of CymaBay Therapeutics, Inc. (Nasdaq: CBAY) for an estimated total equity value of about $4.3 billion. This strategic move enhances Gilead’s liver disease portfolio by incorporating CymaBay’s leading investigational product, seladelpar,…
Today, it was announced that Ono has initiated a comprehensive collaboration for drug discovery with the University of Oxford in Oxfordshire, UK. This collaboration aims to explore and validate drug discovery seeds, as well as to obtain screening compounds to…
Bio-Techne Corporation (NASDAQ: TECH) has announced today that its Molecular Diagnostics Division, Asuragen, has successfully obtained Class C Certification under the new European Union In Vitro Diagnostic Regulation (IVDR) for its QuantideX® qPCR BCR-ABL IS Kit. This certification marks a…
In a strategic move towards advancing regenerative agriculture, Bayer has announced a partnership with Trinity Agtech, a UK-based company. This collaboration aims to leverage Trinity Agtech’s platform, Sandy, as a cornerstone in Bayer’s Carbon Initiative across the EMEA region, facilitating…
Viatris Inc. recently concluded agreements for a comprehensive global research and development collaboration with Idorsia Ltd (SIX: IDIA), a transaction that was finalized on March 15, 2024. For detailed information regarding this significant transaction, please consult Viatris’ Annual Report on…
